Sharing your home with a cat has long been celebrated for alleviating stress and providing emotional solace but emerging research suggests that our feline companions may also hold vital clues to combating certain human cancers.
By examining tumours in domestic cats, scientists are uncovering genetic parallels that could accelerate breakthroughs in oncology, forging an extraordinary link between human health and the well-being of our beloved pets.
Sharing your home with a cat has long been associated with stress reduction and emotional support but recent research indicates that our feline companions could provide profound insights into the treatment of certain human cancers.
A study published on Thursday in Science investigated cancers in domestic cats and revealed striking parallels with how the disease manifests in humans.
While previous research has explored similar correlations in dogs, comparatively little attention has focused on cats, noted co-author Louise van der Weyden, a scientist at the British Welcome Sanger Institute.
“Cats constitute an excellent model for disease research,” Van der Weyden told AFP. “They inhabit the same environments as humans, including exposure to pollutants such as second-hand smoke, and often develop ailments we observe in people, including cancer accompanied by conditions such as diabetes or cardiovascular disease.”
Guided by this principle, the international research consortium analysed tumour specimens from nearly 500 domestic cats across five countries. The study encompassed 13 distinct cancer types, including neoplasms of the brain, breast, lung, and skin.
Since cancers arise from genetic aberrations, researchers examined the DNA of feline tumour cells for markers previously identified in human oncology.
Several remarkable parallels emerged particularly in breast cancer. Over half of the feline mammary tumours exhibited mutations in the FBXW7 gene, a mutation already recognised in humans. While relatively rare among women, this mutation is notably aggressive.
“It mirrors human biology with remarkable fidelity,” Van der Weyden explained. “For women with this mutation, the findings are highly encouraging, as they may open avenues for targeted therapies.”
Clinical trials for rare genetic mutations in humans are often constrained by the limited patient cohort. However, the prevalence of the FBXW7 mutation in cats allows therapies to be tested more extensively in veterinary settings.
Van der Weyden remarked with a smile that she would be “more inclined to trust a drug validated in cats than in mice.”
Encouraged by these parallels, Swiss researchers conducted further experiments on the feline samples, finding that two chemotherapy regimens demonstrated significant efficacy against tumours carrying the FBXW7 mutation.
While additional validation is necessary, these drugs are already approved for both human and veterinary use, suggesting that translational benefits could be realised swiftly for women and cats alike.
Professor Harikrishna Nakshatri, a breast cancer researcher at Indiana University, described the findings as “fascinating,” emphasising their potential to deepen understanding of cancer pathogenesis.
Specifically, the study could illuminate the interplay between genetic predispositions and environmental factors, frequently implicated in disease onset.
For Van der Weyden, the research represents a prospective “win-win” for humans and their cherished pets. “Genomically, we are remarkably similar, and the tumours we develop are strikingly analogous,” she said. “Insights gained in one species can be leveraged to advance therapeutic strategies in the other.”
